Theranostic Folate-Targeted Doxorubicin-Loaded MIL-88A@CuFeO Nanohybrids, a pH-Sensitive, Core-Shell, Mesoporous Drug Delivery Platform with Dual-Modal T1-T2MRI and Optical Imaging Contrast Properties: An In Vitro and In Vivo Cancer Study.
Multifunctional magneto-theranostic nanoplatform, with integrate imaging and therapy in simple platform offer transformative potential for precision cancer management due to their strong magnetic prop
APA
Rezvan M, Kefayat A, et al. (2026). Theranostic Folate-Targeted Doxorubicin-Loaded MIL-88A@CuFeO Nanohybrids, a pH-Sensitive, Core-Shell, Mesoporous Drug Delivery Platform with Dual-Modal T1-T2MRI and Optical Imaging Contrast Properties: An In Vitro and In Vivo Cancer Study.. ACS applied bio materials, 9(4), 2058-2078. https://doi.org/10.1021/acsabm.5c01914
MLA
Rezvan M, et al.. "Theranostic Folate-Targeted Doxorubicin-Loaded MIL-88A@CuFeO Nanohybrids, a pH-Sensitive, Core-Shell, Mesoporous Drug Delivery Platform with Dual-Modal T1-T2MRI and Optical Imaging Contrast Properties: An In Vitro and In Vivo Cancer Study.." ACS applied bio materials, vol. 9, no. 4, 2026, pp. 2058-2078.
PMID
41628477
Abstract
Multifunctional magneto-theranostic nanoplatform, with integrate imaging and therapy in simple platform offer transformative potential for precision cancer management due to their strong magnetic properties, biocompatibility, and versatile theranostic capabilities. Here, we report for the first time the theranostic application of in situ mesoporous core-shell MIL-88A@CuFeO nanohybrid, as an interesting smart platform for dual-mode T1-T2MRI and optical imaging with quantitative analysis, combined with pH-sensitive targeted drug delivery. The nanohybrid was fabricated via a simple in situ synthesis, where Fe (0) from the CuFeO core serves as a Fe source for MIL-88A shell crystallization in the presence of fumaric acid, producing a mesoporous structure with high porosity and strong magnetism. Fe centers in the MIL-88A shell provide T1 contrast, while the CuFeO core enhances both T1 and T2 signals, achieving robust dual-mode MRI ( = 73.0 mM s, = 700.9 mM s). The mesoporous shell allows pH-sensitive controlled release of doxorubicin, and folate conjugation ensures active tumor targeting, while intrinsic doxorubicin fluorescence enables optical tracking of biodistribution in vivo. Comprehensive in vitro and in vivo evaluations demonstrated high biocompatibility, selective cancer cell uptake, effective pH-responsive drug release, dual-modal MRI and fluorescence contrast, and significant tumor growth inhibition in a triple-negative breast cancer (4T1) mouse model. The nanohybrid's combination of high porosity, strong magnetism, dual T1-T2MRI contrast, targeted drug delivery, and therapeutic efficacy distinguish it from existing theranostic agents. This work highlights a theranostic application of MIL-88A@CuFeO nanohybrids, demonstrating their potential as a unique multifunctional platform for precise cancer diagnosis and treatment.
MeSH Terms
Doxorubicin; Animals; Humans; Hydrogen-Ion Concentration; Magnetic Resonance Imaging; Optical Imaging; Folic Acid; Mice; Porosity; Copper; Theranostic Nanomedicine; Biocompatible Materials; Contrast Media; Antibiotics, Antineoplastic; Drug Delivery Systems; Drug Screening Assays, Antitumor; Materials Testing; Ferric Compounds; Cell Proliferation; Particle Size; Mice, Inbred BALB C; Metal-Organic Frameworks; Surface Properties; Female; Cell Survival; Antineoplastic Agents; Drug Carriers